These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27732125)

  • 1. Undermining Value-Based Purchasing - Lessons from the Pharmaceutical Industry.
    Dafny LS; Ody CJ; Schmitt MA
    N Engl J Med; 2016 Nov; 375(21):2013-2015. PubMed ID: 27732125
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of drug regimen costs between the Medicare prescription discount program and other purchasing systems.
    Hayes JM; Walczak H; Prochazka A
    JAMA; 2005 Jul; 294(4):427-8. PubMed ID: 16046648
    [No Abstract]   [Full Text] [Related]  

  • 3. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 4. Lower Prices and Greater Patient Access - Lessons from Germany's Drug-Purchasing Structure.
    Robinson JC
    N Engl J Med; 2020 Jun; 382(23):2177-2179. PubMed ID: 32492300
    [No Abstract]   [Full Text] [Related]  

  • 5. Medicare prescription drug plan costs and affordability--2007.
    Davis MM
    J Gen Intern Med; 2007 Aug; 22(8):1221-2. PubMed ID: 17497191
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug companies' patient-assistance programs--helping patients or profits?
    Howard DH
    N Engl J Med; 2014 Jul; 371(2):97-9. PubMed ID: 25006717
    [No Abstract]   [Full Text] [Related]  

  • 7. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indication-specific Drug Pricing - Simple in Theory, Complex in Reality.
    Kwon S
    Manag Care; 2018 May; 27(5):23-25. PubMed ID: 29763404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare and drug pricing.
    Iglehart JK
    N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
    [No Abstract]   [Full Text] [Related]  

  • 10. Senate GOP tosses drug bill. Law would have let Medicare negotiate costs directly.
    DoBias M
    Mod Healthc; 2007 Apr; 37(17):12. PubMed ID: 17479495
    [No Abstract]   [Full Text] [Related]  

  • 11. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 12. The future of prescription drug cost-sharing: real progress or dropped opportunity?
    Fairman KA
    J Manag Care Pharm; 2008; 14(1):70-82. PubMed ID: 18240885
    [No Abstract]   [Full Text] [Related]  

  • 13. Will reference pricing address the health cost conundrum?
    Iglehart JK
    Health Aff (Millwood); 2003; 22(3):7-8. PubMed ID: 12757267
    [No Abstract]   [Full Text] [Related]  

  • 14. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
    Robinson JC
    N Engl J Med; 2021 Nov; 385(22):2017-2019. PubMed ID: 34797614
    [No Abstract]   [Full Text] [Related]  

  • 15. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 16. Copayment coupons undermine formularies.
    Manag Care; 2011 Dec; 20(12):63. PubMed ID: 22259878
    [No Abstract]   [Full Text] [Related]  

  • 17. Prescription drug pricing: the consumer perspective.
    Searing A
    N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
    [No Abstract]   [Full Text] [Related]  

  • 18. Value-Based Pricing and Patient Access for Specialty Drugs.
    Robinson JC; Howell S; Pearson SD
    JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
    [No Abstract]   [Full Text] [Related]  

  • 19. CMS retreats on Part D rule intended to reduce drug costs and improve access.
    Dickson V
    Mod Healthc; 2014 Mar; 44(11):10. PubMed ID: 24830094
    [No Abstract]   [Full Text] [Related]  

  • 20. America's pharmaceutical research companies: keeping the cost of health care down. Pharmaceutical Manufacturers Association.
    Hawaii Med J; 1992 Jan; 51(1):15-16, 19. PubMed ID: 1740387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.